Argus Research Initiates Coverage On Overstock.com with Hold Rating

Argus Research analyst Kristina Ruggeri initiates coverage on Overstock.com (NASDAQ:OSTK) with a Hold rating.

byBenzinga Newsdesk

October 20, 2022

1 minute read

Argus Research analyst Kristina Ruggeri initiates coverage on Overstock.com (NASDAQ:OSTK) with a Hold rating.

News

Penn National Gaming To Open Hollywood Casino York On August 12th

By Bill Haddad

Today, 11:20 PM

Penn National Gaming, Inc. (NASDAQ:PENN)("Penn National" or the "Company") announced today that it expects to open Hollywood Casino York to the public on Thursday, August 12th, at Noon, pending final

PENN

Yunhong CTI Q3 EPS $(0.12) Up From $(0.14) YoY

By Benzinga Newsdesk

Today, 11:20 PM

Yunhong CTI (NASDAQ:CTIB) reported quarterly losses of $(0.12) per share. This is a 14.29 percent increase over losses of $(0.14) per share from the same period last year.

CTIB

Tractor Supply Q4 EPS $1.93 Beats $1.83 Estimate, Sales $3.32B Beat $3.24B Estimate

By Benzinga Newsdesk

Today, 11:20 PM

Tractor Supply (NASDAQ:TSCO) reported quarterly earnings of $1.93 per share which beat the analyst consensus estimate of $1.83 by 5.46 percent. This is a 17.68 percent increase over earnings of $1.64 per share from the

TSCO

FDA
News

Novartis Says Co Reports Clinically Relevant Improvement In Median Overall Survival Data In Final Analysis Of Pivotal NETTER-1 Study With Targeted Radioligand Therapy Lutathera

By Benzinga Newsdesk

Today, 11:20 PM

Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR

NVS

Argus Research Initiates Coverage On Overstock.com with Hold Rating

Related Posts

Penn National Gaming To Open Hollywood Casino York On August 12th

Yunhong CTI Q3 EPS $(0.12) Up From $(0.14) YoY

Tractor Supply Q4 EPS $1.93 Beats $1.83 Estimate, Sales $3.32B Beat $3.24B Estimate

Novartis Says Co Reports Clinically Relevant Improvement In Median Overall Survival Data In Final Analysis Of Pivotal NETTER-1 Study With Targeted Radioligand Therapy Lutathera